Predisposition to Thrombophilia and Hypofibrinolysis in Pulmonary Embolism: Analysis of Inherited Factors

1. Torbicki A, Perrier A, Konstantin ides S, Agnelli G, Galie N, Pruszczyk P, et al. Guidelines on the diagnosis and management of acute pulmonary embolism.The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Eu Heart J. 2008;29:2276-315.10.1093/eurheartj/ehn310Search in Google Scholar

2. Goldhaber SZ. Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol. 2012;25(3):235-42.10.1016/j.beha.2012.06.007Search in Google Scholar

3. Anderson FA Jr, Wheeler HB, Goldbeig RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med. 1991; 151:933-8.10.1001/archinte.1991.00400050081016Search in Google Scholar

4. Goldhaber SZ, Hennekens CH, Evans DA, Newton EC, Godleski JJ. Factors associated with correct antemortem diagnosis of major pulmonary embolism. Am J Med. 1982;73(6):822-6.10.1016/0002-9343(82)90764-1Search in Google Scholar

5. Rodger M, Wells PS. Diagnosis of pulmonary embolism. Thromb Res. 2001; 103(6): V225 -3 8.10.1016/S0049-3848(01)00326-7Search in Google Scholar

6. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registiy (ICOPER). Lancet. 1999;353:1386-9.10.1016/S0140-6736(98)07534-5Search in Google Scholar

7. Dulicuek P, Maly J, Pesuavova L, Pecka M. Prevalence of inherited thrombophilia in young thrombosis patients from the East Bohemian region. Blood Coagul Fibrinolysis. 2002; 13(6):569-73.10.1097/00001721-200209000-0001312192310Search in Google Scholar

8. British Thoracic Society Standards of Care Committee. Pulmonary Embolism Guideline Development Group. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax. 2003;5 8:470-84.10.1136/thorax.58.6.470174669212775856Search in Google Scholar

9. Rosendaal FR, KosterT, Vandenbrouck JP, Reitsma PH. High risk of thrombosis in patients homozygous for lactor V Leiden (activated protein C resistance). Blood. 1995;85:1504-8.10.1182/blood.V85.6.1504.bloodjournal8561504Search in Google Scholar

10. Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Factor V Leiden andtherisk for venous thromboembolism in the adult Danish population. Ann Intern Med. 2004; 140:330-7.10.7326/0003-4819-140-5-200403020-0000814996674Search in Google Scholar

11. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q.JBiolChem. 1995;270:4053-7.Search in Google Scholar

12. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica. 2002;87:1095-108.Search in Google Scholar

13. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;8 8( 10):3698-703.10.1182/blood.V88.10.3698.bloodjournal88103698Search in Google Scholar

14. Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med. 2007; 167(5) :497-501.10.1001/archinte.167.5.497Search in Google Scholar

15. Castro R, Rivera I, Blom H. J, Jakobs C, De Almeida I. T. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview. J Inherit MetabDis. 2006;29(l):3-20.10.1007/s10545-006-0106-5Search in Google Scholar

16. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. JAMA. 2004 ;291:565-75.10.1001/jama.291.5.565Search in Google Scholar

17. Fermo I, D'Angelo SV, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early onset venous and arterial occlusive disease. Ann Intern Med. 1995;123:747-53.10.7326/0003-4819-123-10-199511150-00002Search in Google Scholar

18. De Bree A, Verschuren WM, Bjorke-Monsen AL, Van der Put NM, Heil SG, Trijbels FJ, et al. Effect of the methylenetetrahydrofolate reductase 677C-->T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample. Am JClinNutr. 2003;77:687-93.10.1093/ajcn/77.3.687Search in Google Scholar

19. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. P1A1/A2 polymorphism of platelet glycoprotein Ilia and risk of myocardial infarction, stroke and venous thrombosis. Lancet. 1997;349:385-58.10.1016/S0140-6736(97)80010-4Search in Google Scholar

20. Renner W, Winkler M, Hoffinann C, Koppel H, Seinost G, Brodmann M, et al. The P1A1/A2 polymorphism of platelet glycoprotein Ilia is not associated with deep venous thrombosis. Int Angiol. 2001 ;20(2): 148-51.Search in Google Scholar

21. Francis C. Plasminogen activator inhibitor-1 levels and polymorphisms. Association with venous thromboembolism. Arch Pathol Lab Med. 2002; 126(11): 1401-4.10.5858/2002-126-1401-PAILAP12421149Search in Google Scholar

22. Tsantes AE,Nikolopoulos GK, BagosPG,RaptiE, Mantzios G, Kapsimali V, et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb Haemost 2007;97(6):907-13.10.1160/TH06-12-0745Search in Google Scholar

23. Komsa-Penkova R,Kovacheva- Kotseva K, Angelova S, SavovA, Scmionova M. Selected methods of DN A analysis and clinical applications. Pleven: MU-Pleven; 2004.Search in Google Scholar

24. Ivanov P, Komsa-Penkova R, Ivanov Y, Ivanov I, Matkov O, Beshev L [4G/5G polymorphism in the gene for plasminogen activator inhibitor-1 in patients it may be a deep vein thrombosis]. Modcma Medicina. 2009;60(l-2):35-9. [in Bulgarian].Search in Google Scholar

25. Kwok S, Higuchi R. Avoiding false-positives with PCR. Nature. 1989;339:237-8.10.1038/339237a02716852Search in Google Scholar

26. Ivanov P, Komsa-Penkova R, Kovacheva K, Ivanov Y, Stoyanova A, Ivanov I, Pavlov P, Glogovska P, Nojarov V. Impact of genetic factors on pulmonary embolism - early onset and recurrent incidences. Lung. 2008;186(1)^7-36.10.1007/s00408-007-9061-718097719Search in Google Scholar

27. Ridker PM, Miletich JP, Stampfcr MJ, Goldhabcr SZ, Lindpaintncr K, Hennekeas CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800-2.10.1161/01.CIR.92.10.2800Search in Google Scholar

28. Perry SL, Ortel TL. Clinical and laboratory evaluation of thrombophilia Clin Chest Med 2003;24:153-70.Search in Google Scholar

29. Nizankowska-Mogilnicka E, Adamek L, Grzanka P, Domagala T.B, Sanak M , Krzanowski M, Szczcklik A. Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis. EurRespir J. 2003 ;21(1 ):25-30.10.1183/09031936.03.0003430212570104Search in Google Scholar

30. Ogzulgcn IK, Eim NN , Akar N, Dcmircl K, Ki-tapei M. The role of thrombophilic risk factors in the severity of pulmonary embolism. Eur Respir J. 2002; 19(4):705-11.Search in Google Scholar

31. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166(7):729-36.10.1001/archinte.166.7.72916606808Search in Google Scholar

32. Roscndaal FR, Doggen CJ,ZivelinA, Arruda VR, Aiach M, Siscovick DS, ct al. Geographic distribution of the 20210 G to A prothrombin variant. Thro mb Haemost. 1998;79(4):706-70.10.1055/s-0037-1615049Search in Google Scholar

33. De Stefano V, Martinclli I, Mannucci PM, Pacia-roni K, Rossi E, Chiusolo P, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol. 2001; 113(3 ):630-5.10.1046/j.1365-2141.2001.02827.x11380448Search in Google Scholar

34. Kwak SH, Wang XQ, He Q, Fang WF, Mitra S, Bdcir K, et al. Plasminogen activator inhibitor-1 potentiates LPS-inducod neutrophil activation through a JNK-mediated pathway. Thromb Haemost. 2006;95(5):829-35.10.1160/TH05-12-0782Search in Google Scholar

35. Pcdroja BS, Kang LE, Imas AO, Carmeliet P, Bernstein AM. Plasminogen activator inhibitor-1 regulates integrin alpha v bcta3 expression and autocrine transforming growth factor beta signaling. J Biol Chem. 2009 ^ 84(31):20708-17.10.1074/jbc.M109.018804274283619487690Search in Google Scholar

36. Abboud N, Ghazouani L, Saidi S, Ben-Hadj-Kha-lifa S, Addad F, Almawi WY, ctal. Association of PAI-1 4G/5G and - 844G/Agcne poly-morphlsms and changes in PAI -1 /tissue plasminogen activator levels in myocardial infarction: a case-control study. Genet Test Mol Biomarkers. 2010;14( 1):23-7.10.1089/gtmb.2009.003919929406Search in Google Scholar

37. Saidi S, Slamia LB, Mahjoub T, Ammou SB, Almawi WY. Association of PAI-1 4G/5G and -844G/A gene polymorphism and changes in PAI-1A PA levels in stroke: a case-control study. Stroke Ccrebrovasc Dis. 2007;16(4): 153-9.10.1016/j.jstrokecerebrovasdis.2007.02.00217689411Search in Google Scholar

38. Tsantes AE, Nikolopoulos GK, Bagos PG, Bono-vas S, Koptcridcs P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res. 2008;122(6):736-42.10.1016/j.thromres.2007.09.005Search in Google Scholar

39. Eichingcr S, Pabingcr I, Stiimpflcn A, Hirschl M, Bialonczyk C, Schneider B, et al. The risk of recurrent venous thromboembolism in patients with and without factorV Leiden. Thromb Haemost. 1997;77:624-8.10.1055/s-0038-1656023Search in Google Scholar

40. Lindmarkcr P, Schulman S, Sten-Linder M, Wiman B, Egbcrg N, Johnsson H., et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost. 1999;81:684-9.10.1055/s-0037-1614554Search in Google Scholar

41. Simioni P, Prandoni P, Lensing AW, Scudcllcr A, Sardclla C, Prias MH, et al. The risk of recurrent venous thromboembolism in patients with an Arg506->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997;336:399-403.10.1056/NEJM199702063360602Search in Google Scholar

42. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 1992;340:873-6.10.1016/0140-6736(92)93285-USearch in Google Scholar

43. Prandoni P, Leasing AW, Cogo A, Cuppini S, Villalta S, Carta M,Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinicalcourse of acute deep venous thrombosis. AnnlntcrnMod. 1996;125:1-7.Search in Google Scholar

44. Geno J. Merli. Pathophysiology of venous thrombosis, thrombophilia, and the diagnosis of deep vein thrombosis-pulmonarycmbolism in the elderly. Clin Geriatr Med. 2006;22:75-92. 10.1016/j.cger.2005.09.01216377468Search in Google Scholar